TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Obtaining medications prescribed at discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Correct use of medications prescribed at discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Arranging follow-up appointment with primary care provider
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Attendance at visit with primary care provider after discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Primary performance assessment of TetraGraph device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal voided volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: One Leg Stance Test (OLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest High-Resolution Computed Tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial Blood Gas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Caregiver Competency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Caregiver Mastery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: amount of food chosen
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: amount of social time chosen
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of Participants Reporting Serious Adverse Events (SAEs) From Day 1 Through Day 337
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Clinical Safety Laboratory Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Unsolicited Non-Serious Adverse Events at Any Time From Day 1 to Day 197
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of dark adaptation of the pupil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvascular flow index (MFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparative increase of baseline Hb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Motor evoked potentials (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Volitional electromyographic (EMG) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response to closed-loop stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2 Year Progression-Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Narcotics Consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Any Past Year Physical Intimate Partner Violence Perpetration
Endpoint domain: Adverse events/effects
Primary endpoint: Any Past Year Sexual Intimate Partner Violence Perpetration
Endpoint domain: Adverse events/effects
Primary endpoint: Past Year Severe Sexual and/or Physical Intimate Partner Violence Perpetration
Endpoint domain: Adverse events/effects
Primary endpoint: Monitoring of erythrocyte level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Monitoring of leukocyte level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Monitoring of platelet level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Asthma Control Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: peak plasma concentrations (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the time vs. plasma concentration curve from 0 to 24 hr (AUCall)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the time vs. plasma concentration curve from 0 to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parameter H2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation Time (Seconds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to Confirm the Placement of the Tracheal Tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Percent Intelligibility of Speech Over 4 Months
Endpoint domain: Life impact
Endpoint subdomain: Communication functioning
Primary endpoint: Change in Rate of Intelligible Speech Over 4 Months
Endpoint domain: Life impact
Endpoint subdomain: Communication functioning
Primary endpoint: Change in Speech Acceptability Over 4 Months
Endpoint domain: Life impact
Endpoint subdomain: Communication functioning
Primary endpoint: Change in Speech and Swallowing Over 4 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of Overall Newly Occurring GI Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of acute myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Apathy Evaluation Scale (AES) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Early detection of lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Non-haem iron absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes From Baseline Hypoxic Volume (HV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity measured by increase of temperature and/or appearance of rash
Endpoint domain: Adverse events/effects
Primary endpoint: Viral load response assessed by PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Days alive out of hospital 6 months post discharge
Endpoint domain: Mortality/survival
Primary endpoint: Change in mean power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fatigue index
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: H pylori load reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Comparison of seizure annotations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent change in AUSCAN pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Non-HDL Cholesterol Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Radiographic Total Score to Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to AEs During the Open-Label Period
Endpoint domain: Adverse events/effects
Primary endpoint: Annualized Aggregate Relapse Rate (ARR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to First Confirmed Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Left Ventricular Endsystolic Diameter (LVED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Toronto Alexithymia Scale-20 (TAS-20)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Levels of Emotional Awareness Scale (LEAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Elderly Mobility Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with post surgical trauma
Endpoint domain: Adverse events/effects
Primary endpoint: second diagnostic hysteroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in 24-hour Mean Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variance of skin erythema measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Absolute change in red reflectance of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUCτ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Plasma Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: risk of multisystem organ failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in the Daily Major Symptom Score (MSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite outcome of urinary tract infection symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Average AM/PM PRIOR Nasal Congestion Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tinetti Mobility Test Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Comfort using the Socket Fit Comfort Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Satisfaction and Quality of life using the Prosthetic Evaluation Questionnaire (PEQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in mobility as measured by the 10-meter walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Average Mucociliary Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak plasma concentration of JNJ 40411813
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach the peak plasma concentration of JNJ 40411813
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants positive response to nasal provocation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative Chest Drainage Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lengthening control index (LCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of circulating tissue factor (TF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brief Pain Inventory pain interference score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of stent struts with late acquired malaposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the curve (AUC(0 to infinity))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serious condition requiring early intervention
Endpoint domain: Mortality/survival
Primary endpoint: Change in sphincter defect 3-point radial angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sphincter defect Stark Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: intraoperative consumption of opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With a Response (Complete Response and Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TSH (thyrotropin-stimulating-hormone)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Characterisation of cellular phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Characterisation of functional phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Uterine quiescence at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Are Progression Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Gross Motor Function Measure (GMFM)-88
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Duration of MRF Sequence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Patients Developing HER2+ Metastases
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of Cardio-RM identifying ischemic territories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Technical success rate of the fusion process
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Technical success rate of the overall RFA procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of complete ablation of the tumor after 1 month clinical follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Demographic parameters before dapagliflozin initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Counts of microorganisms in genital tracts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hardness of cavity on tooth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nature and outcome of skin lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Posttraumatic Stress Disorder Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in self-reported IBS symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUA Symptom Score Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of decrease of mean arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Retention of components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First occurrence of atrial fibrillation (AF) requiring anticoagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: First occurrence of bradyarrhythmia requiring cardiac pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: First occurrence of supraventricular arrhythmia requiring drug treatment or ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: First occurrence of non-sustained ventricular tachyarrhythmia requiring drug treatment, ICD implantation or ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference between prediction and actual postoperative outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Home Situations Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Vineland Daily Living Skills Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Age of adrenarche signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Age of gonadarche signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean Change From Baseline in Hb (g/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number (%) of Participants Who Achieved a Hb Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adjusted Mean Change From Baseline in the Number of Migraine Headache Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Surgical Treatment Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: EORTC QLQ-C30 score change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Relative Prolongation Ability Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent days abstinent from alcohol or illicit drugs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement of type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in sCD14 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Knee Cartilage Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency of Visual Evoked Potential waveforms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amplitude of Visual Evoked Potential waveforms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Daily life functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Depression level measured by CES-D
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety level measured by BAI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of polymorphisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients experiencing acute postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with recurrent hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in HDL oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in proteomics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in MBT following Propranolol treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MBT correlation to clinical events after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision Regret
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decision conflict
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Subjects With Forteo B Pen Complaints at 8 Weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Forteo B Pen Complaints at 46 Weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Pediatric Quality of Life Inventory Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Amount of astigmatism reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute GvHD grade 3 & 4
Endpoint domain: Adverse events/effects
Primary endpoint: serum alpha tumor necrosis factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-1 Beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Confirmation of 18F-MFBG as a hNET imaging agent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in total body water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variations in body resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Main adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with treatment-related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with worsening laboratory values
Endpoint domain: Adverse events/effects
Primary endpoint: toxicity of Abraxane
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of intravenous insulin infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sobriety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of adolescent/caregiver pairs who attend Family Connections
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of participants who would recommend the Family Connections program
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life